Health Catalyst (NASDAQ:HCAT) Price Target Lowered to $10.00 at Citigroup

Health Catalyst (NASDAQ:HCAT) had its target price decreased by Citigroup from $10.50 to $10.00 in a report released on Friday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.

Several other equities analysts have also recently weighed in on the company. Evercore ISI raised their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Royal Bank of Canada raised their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a report on Wednesday. Stephens raised their price target on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $11.45.

Health Catalyst Stock Down 6.4 %

NASDAQ HCAT opened at $6.89 on Friday. The stock’s 50-day moving average price is $7.79 and its 200-day moving average price is $7.52. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a 52 week low of $5.42 and a 52 week high of $11.41. The company has a market capitalization of $419.24 million, a P/E ratio of -5.10 and a beta of 1.36.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same period last year, the business earned ($0.22) EPS. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, equities research analysts predict that Health Catalyst will post -0.33 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Linda Llewelyn sold 6,442 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $7.88, for a total transaction of $50,762.96. Following the completion of the sale, the insider now directly owns 98,702 shares of the company’s stock, valued at approximately $777,771.76. This trade represents a 6.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Benjamin Landry sold 19,268 shares of Health Catalyst stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $160,309.76. Following the sale, the general counsel now directly owns 72,250 shares of the company’s stock, valued at approximately $601,120. This trade represents a 21.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 76,051 shares of company stock valued at $612,614. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Primecap Management Co. CA increased its holdings in shares of Health Catalyst by 14.7% in the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after acquiring an additional 305,079 shares during the period. Janney Montgomery Scott LLC acquired a new position in shares of Health Catalyst in the 3rd quarter valued at about $897,000. Fred Alger Management LLC acquired a new position in shares of Health Catalyst in the 3rd quarter valued at about $6,858,000. Millrace Asset Group Inc. acquired a new position in Health Catalyst in the 3rd quarter worth about $1,568,000. Finally, Point72 Asset Management L.P. raised its holdings in Health Catalyst by 69.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock worth $4,208,000 after purchasing an additional 211,805 shares during the period. 85.00% of the stock is owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.